VTVT - Paul Sekhri to join vTv Therapeutics as CEO

• Paul Sekhri has been appointed as president and CEO of clinical-stage biopharmaceutical company vTv Therapeutics ( NASDAQ: VTVT ).
• Sekhri assumes the role on August 1, 2022, replacing interim CEO Rich Nelson, who will continue as EVP, Corporate Development and as a member of the board of directors.
• He hold nearly 30 years of healthcare experience, including serving as president and CEO of several healthcare companies such as eGenesis, Lycera, Cerimon Pharmaceuticals, as well as senior business development and strategy roles at Sanofi, Teva Pharmaceutical Industries, TPG Biotech, Cerimon, Ariad Pharmaceuticals and Novartis Pharma.
• The appointment comes at a time when vTv Therapeutics ( VTVT ) is set to launch Phase 3 pivotal studies for its most advanced product, TTP399. TTP399 has received Breakthrough Therapy designation by the U.S. FDA as an oral adjunctive therapy for the treatment of T1D.

For further details see: